Katharina Rox

Dr. Katharina Rox

Helmholtz Centre for Infection Research (HZI), Braunschweig, Germany
orcid

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 April 2020 in Science
Verified
Journal Article
Open access
PDF file
LZLinlin Zhang
Linlin Zhang
DLDaizong Lin
Daizong Lin
XSXinyuanyuan Sun
Xinyuanyuan Sun
UCUte Curth
Ute Curth
CDChristian Drosten
Christian Drosten
RHRolf Hilgenfeld
Rolf Hilgenfeld
The coronavirus disease 2019 (COVID-19) pandemic caused by severe acute respiratory syndrome–coronavirus 2 (SARS-CoV-2) is a global health emergency. An attractive drug target among coronaviruses is the main protease (M pro , also called 3CL pro ) because of its essential role in processing the polyproteins that are translated from the viral RNA. We report the x-ray structures of the unliganded SARS-CoV-2 M pro and its complex with an α-ketoamide inhibitor. This was derived from a previously designed inhibitor but with the P3-P2 amide bond incorporated into a pyridone ring to enhance the half-life of the compound in plasma. On the basis of the unliganded structure, we developed the lead compound into a potent inhibitor of the SARS-CoV-2 M pro . The pharmacokinetic characterization of the optimized inhibitor reveals a pronounced lung tropism and suitability for administration by the inhalative route.

16 December 2019 in Nature Chemistry
Verified
Journal Article
Closed access
PDF file
PLPhilipp Le
Philipp Le
EKElena Kunold
Elena Kunold
RMRobert Macsics
Robert Macsics
KRKatharina Rox
Katharina Rox
MJMegan C. Jennings
Megan C. Jennings
SSStephan A. Sieber
Stephan A. Sieber

22 January 2018 in Journal of the American Chemical Society
Verified
Journal Article
Open access
RSRoman Sommer
Roman Sommer
SWStefanie Wagner
Stefanie Wagner
KRKatharina Rox
Katharina Rox
AVAnnabelle Varrot
Annabelle Varrot
DHDirk Hauck
Dirk Hauck
ATAlexander Titz
Alexander Titz
The opportunistic Gram-negative bacterium Pseudomonas aeruginosa is a leading pathogen for infections of immuno-compromised patients and those suffering from cystic fibrosis. Its ability to switch from planktonic life to aggregates, forming the so-called biofilms, is a front-line mechanism of antimicrobial resistance. The bacterial carbohydrate-binding protein LecB is an integral component and necessary for biofilm formation. Here, we report a new class of drug-like low molecular weight inhibitors of the lectin LecB with nanomolar affinities and excellent receptor binding kinetics and thermodynamics. This class of glycomimetic inhibitors efficiently blocked biofilm formation of P. aeruginosa in vitro while the natural monovalent carbohydrate ligands failed. Furthermore, excellent selectivity and pharmacokinetic properties were achieved. Notably, two compounds showed good oral bioavailability and high compound concentrations in plasma and urine were achieved in vivo.

25 September 2019 in Journal of Medicinal Chemistry
Verified
Journal Article
Open access
RSRoman Sommer
Roman Sommer
KRKatharina Rox
Katharina Rox
SWStefanie Wagner
Stefanie Wagner
DHDirk Hauck
Dirk Hauck
SHSarah Henrikus
Sarah Henrikus
ATAlexander Titz
Alexander Titz
Biofilm formation is a key mechanism of antimicrobial resistance. We have recently reported two classes of orally bioavailable C-glycosidic inhibitors of the Pseudomonas aeruginosa lectin LecB with anti-biofilm activity. They proved efficient in target binding, were metabolically stable, non-toxic, selective and potent in inhibiting formation of bacterial biofilm. Here, we designed and synthesized 6 new carboxamides and 24 new sulfonamides for a detailed structure-activity-relationship for two clinically representative LecB variants. Sulfonamides generally showed higher inhibition compared to carboxamides which was rationalized based on crystal structure analyses. Substitutions at the thiophenesulfonamide increased binding through extensive contacts with a lipophilic protein patch. These metabolically stable compounds showed a further increase in potency towards the target and in biofilm inhibition assays. In general, we established the structure-activity relationship for these promising anti-biofilm agents and showed that modification of the sulfonamide residue bears future optimization potential.

18 March 2021 in Advanced Science
Verified
Journal Article
Open access
PDF file
CSChristian Schütz
Christian Schütz
DHDuy‐Khiet Ho
Duy‐Khiet Ho
MHMostafa Mohamed Hamed
Mostafa Mohamed Hamed
AAAhmed Saad Abdelsamie
Ahmed Saad Abdelsamie
TRTeresa Röhrig
Teresa Röhrig
MEMartin Empting
Martin Empting
Pseudomonas aeruginosa (PA) infections can be notoriously difficult to treat and are often accompanied by the development of antimicrobial resistance (AMR). Quorum sensing inhibitors (QSI) acting on PqsR (MvfR) – a crucial transcriptional regulator serving major functions in PA virulence – can enhance antibiotic efficacy and eventually prevent the AMR. An integrated drug discovery campaign including design, medicinal chemistry‐driven hit‐to‐lead optimization and in‐depth biological profiling of a new QSI generation is reported. The QSI possess excellent activity in inhibiting pyocyanin production and PqsR reporter‐gene with IC50 values as low as 200 and 11 × 10−9 m, respectively. Drug metabolism and pharmacokinetics (DMPK) as well as safety pharmacology studies especially highlight the promising translational properties of the lead QSI for pulmonary applications. Moreover, target engagement of the lead QSI is shown in a PA mucoid lung infection mouse model. Beyond that, a significant synergistic effect of a QSI‐tobramycin (Tob) combination against PA biofilms using a tailor‐made squalene‐derived nanoparticle (NP) formulation, which enhance the minimum biofilm eradicating concentration (MBEC) of Tob more than 32‐fold is demonstrated. The novel lead QSI and the accompanying NP formulation highlight the potential of adjunctive pathoblocker‐mediated therapy against PA infections opening up avenues for preclinical development.

8 February 2024 in Nature Communications
Verified
Journal Article
Open access
PDF file
SSSvenja M. Sake
Svenja M. Sake
XZXiaoyu Zhang
Xiaoyu Zhang
MRManoj Kumar Rajak
Manoj Kumar Rajak
MUMelanie Urbanek-Quaing
Melanie Urbanek-Quaing
ACArnaud Carpentier
Arnaud Carpentier
TPThomas Pietschmann
Thomas Pietschmann
Respiratory syncytial virus (RSV) is a common cause of acute lower respiratory tract infection in infants, older adults and the immunocompromised. Effective directly acting antivirals are not yet available for clinical use. To address this, we screen the ReFRAME drug-repurposing library consisting of 12,000 small molecules against RSV. We identify 21 primary candidates including RSV F and N protein inhibitors, five HSP90 and four IMPDH inhibitors. We select lonafarnib, a licensed farnesyltransferase inhibitor, and phase III candidate for hepatitis delta virus (HDV) therapy, for further follow-up. Dose-response analyses and plaque assays confirm the antiviral activity (IC50: 10-118 nM). Passaging of RSV with lonafarnib selects for phenotypic resistance and fixation of mutations in the RSV fusion protein (T335I and T400A). Lentiviral pseudotypes programmed with variant RSV fusion proteins confirm that lonafarnib inhibits RSV cell entry and that these mutations confer lonafarnib resistance. Surface plasmon resonance reveals RSV fusion protein binding of lonafarnib and co-crystallography identifies the lonafarnib binding site within RSV F. Oral administration of lonafarnib dose-dependently reduces RSV virus load in a murine infection model using female mice. Collectively, this work provides an overview of RSV drug repurposing candidates and establishes lonafarnib as a bona fide fusion protein inhibitor.